Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000825876 | SCV000967361 | uncertain significance | not specified | 2018-05-18 | criteria provided, single submitter | clinical testing | The p.Ser1742Thr variant in CACNA1D has not been reported in individuals with he aring loss, but was identified in 0.02% (6/24024) of African chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs7 59409255). Computational prediction tools and conservation analysis do not provi de strong support for or against an impact to the protein. In summary, the clini cal significance of the p.Ser1742Thr variant is uncertain. ACMG/AMP Criteria app lied: PM2_Supporting. |
Labcorp Genetics |
RCV001858405 | SCV002192902 | likely benign | not provided | 2024-11-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004029191 | SCV004915198 | uncertain significance | Inborn genetic diseases | 2021-08-12 | criteria provided, single submitter | clinical testing | The c.5225G>C (p.S1742T) alteration is located in exon 43 (coding exon 43) of the CACNA1D gene. This alteration results from a G to C substitution at nucleotide position 5225, causing the serine (S) at amino acid position 1742 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |